2024 Approvals

Xolremdi: A New Treatment for WHIM Syndrome Approved on April 26, 2024

Jasmine C

28 Oct 2025 — 1 min read

ChatGPT Image Aug 4, 2025, 03_20_13 PM

What is it prescribed for?

XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.

What is the name of the drug and what does it do?

Xolremdi (pronounced zohl-REM-dee), (generic name: mavorixafor), is a medication indicated for patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis).

It helps increase the number of circulating mature neutrophils and lymphocytes, improving immune function.

How does it work?

Xolremdi is a CXC chemokine receptor 4 (CXCR4) antagonist. It works by blocking the CXCR4 receptor, which is involved in the retention of white blood cells in the bone marrow.

By inhibiting this receptor, Xolremdi mobilizes neutrophils and lymphocytes from the bone marrow into the bloodstream, enhancing the body’s ability to fight infections and improving overall immune function.

What did the research discover?

Clinical trials demonstrated that Xolremdi significantly increases the number of circulating neutrophils and lymphocytes in patients with WHIM syndrome.

In the trials, patients treated with Xolremdi showed a substantial improvement in their absolute neutrophil count (ANC) and absolute lymphocyte count (ALC).

The trials also reported a reduction in infection rates and an improvement in the overall health status of the patients.

What are some of the side effects?

Thrombocytopenia
Pityriasis
Rash
Rhinitis
Epistaxis
Vomiting
Dizziness

What are the dosage recommendations and how is it prescribed?

Xolremdi is administered orally. The recommended dosage is based on the patient's weight:

For patients weighing more than 50 kg: 400 mg once daily.
For patients weighing 50 kg or less: 300 mg once daily.

Xolremdi should be taken on an empty stomach after an overnight fast and at least 30 minutes before food. The capsules should be swallowed whole without breaking, chewing, or opening them. If a dose is missed, the next dose should be taken as scheduled, without doubling the dose.

Source:

X4 Pharmaceuticals, Inc. Xolremdi (mavorixafor) capsules, for oral use. Prescribing Information. 2024. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218709s000lbl.pdf

Racial Gaps in Stroke Treatment: Who Gets Life-Saving Care?

What Did the Research Discover? This study looked at racial differences in the use of mechanical thrombectomy (MT)—a procedure that removes blood clots from the brain in people experiencing a stroke. Researchers analyzed 889,309 stroke cases in U.S. hospitals between 2006 and 2014 and found that only

Progress with Artificial Retina Implants in Patients with Macular Degeneration

Macular degeneration and retinitis pigmentosa are two major causes of vision loss, and both damage the retina—the layer in the back of the eye that captures light and sends signals to the brain. Once those photoreceptors, called rods and cones, are lost, vision declines. But new research shows that

Don’t Toss Them—Here’s How to Safely Dispose of Unused Medicines

Is your medicine cabinet full of expired drugs or medications you no longer use? The best way to dispose of most types of expired, unwanted or unused medicines is through a drug take-back program. To discard of your prescription or over-the-counter medicines, you can: If you cannot use those options,

Music May Help Lower Dementia Risk in Older Adults, A New Study Suggests

The Connection Between Music and Brain Health As people live longer, more families worry about memory loss and dementia. Scientists are working hard to understand how lifestyle habits—like staying active, socializing, and learning new skills—may help protect the brain. One area that has gained attention is music. Many